This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Implications for a Generic Vaccine

J. Milburn Jessup, MD; Kefeng Qi, MB; Kristine Kanellopoulos; Debra E. Campbell; Karen R. Cleary, MD; Catherine M. Hickey; Christopher L. Reading, PhD; Howard E. Savage, PhD

Arch Surg. 1987;122(12):1435-1439.

Abstract
• The antibody response of patients was used to characterize the autoantigens in human colorectal carcinoma. Twenty-seven primary and 13 metastatic carcinomas with paired normal tissues were extracted and transferred onto nitrocellulose membranes by the Western transfer technique. After the transfers were incubated with the serum of the patient from whom the tumor was derived, autoantigens were indentified by indirect immunoperoxidase staining. All tumors contained at least one autoantigen. Six tumor-associated autoantigens, ranging in molecular weight from 26 to 58 kilodaltons (kD), were identified by antibodies in 25% or more of the sera. Eleven metastases expressed a 41-kD autoantigen that was present in only a third of the extracts of normal liver or lung. Thus, the number of dominant polypeptide autoantigens in colorectal carcinoma is restricted to six molecules. These autoantigens may be organ-associated antigens that are expressed by neoplastic cells. The 41-kD autoantigen may be a potential marker for metastases. A generic vaccine appears to be feasible for colorectal carcinoma since the number of dominant antigens is limited.

(Arch Surg 1987;122:1435-1439)

Author Affiliations
From the Departments of Surgery (Drs Jessup and Qi, and Mss Kanellopoulos and Campbell), Pathology (Dr Cleary), and Hematology (Ms Hickey and Dr Reading), The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston; and Immunology Research Laboratory, Veterans Administration Medical Center, Houston; and Department of Immunology and Microbiology, Baylor College of Medicine, Houston (Dr Savage).

Footnotes
Accepted for publication Aug 24, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 30, 1987.

Reprint requests to Department of Surgery, Box 106, The University of Texas M. D. Anderson Hospital and Tumor Institute, 1515 Holcombe Blvd, Houston, TX 77030 (Dr Jessup).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Carcinoembryonic Antigen Enhances Metastatic Potential of Human Colorectal Carcinoma
Hostetter et al.
Arch Surg 1990;125:300-304.
ABSTRACT  

Tumor Immunization: Improved Results After Vaccine Modified With Recombinant Interferon Gamma
Sigal et al.
Arch Surg 1990;125:308-312.
ABSTRACT